Valneva SE (VALN)

Market Cap	970.26M +64.8%
Revenue (ttm)	205.07M +3.0%
Net Income	-135.25M
EPS	-0.80
Shares Out	86.71M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	33,632
Open	11.46
Previous Close	11.01
Day's Range	10.97 - 11.46
52-Week Range	5.43 - 12.25
Beta	1.27
Analysts	Strong Buy
Price Target	15.75 (+40.75%)
Earnings Date	Mar 18, 2026

About VALN

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; and IXCHIQ/ VLA1553, a single-dose, live-attenuated vaccine for the prevention of disease ca...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: May 6, 2021
• Employees: 700
• Stock Exchange: NASDAQ
• Ticker Symbol: VALN
• Website: https://valneva.com

Financial Performance

In 2025, Valneva SE's revenue was 174.66 million, an increase of 3.00% compared to the previous year's 169.58 million. Losses were -115.19 million, 840.6% more than in 2024.

Financial numbers in EUR

Analyst Summary

According to 4 analysts, the average rating for VALN stock is "Strong Buy." The 12-month stock price target is $15.75, which is an increase of 40.75% from the latest price.

Price Target

$15.75

(40.75% upside)

Analyst Consensus: Strong Buy